Gilead Sciences (GILD) Raw Materials (2009 - 2015)
Gilead Sciences' (GILD) quarterly Raw Materials came in at $1.3 billion in Q4 2015, up 46.53% on a YoY basis from $909.0 million in Q4 2014, and up 46.53% quarter-over-quarter from $909.0 million in Q4 2014.
Analysis
Gilead Sciences (GILD) Raw Materials (2009 - 2015) Analysis & Trends
Gilead Sciences (GILD) has reported Raw Materials for 7 consecutive years, with $1.3 billion the latest figure, recorded in Q4 2015.
- For the quarter ending Q4 2015, Raw Materials rose 46.53% year-over-year to $1.3 billion; the trailing twelve-month figure through Dec 2015 stood at $1.3 billion (up 46.53% YoY), and the FY2015 full-year result was $1.3 billion, up 46.53% from the prior year.
- Raw Materials rose to $1.3 billion in Q4 2015 per GILD's latest filing, from $909.0 million in the prior quarter.
- Across five years, Raw Materials topped out at $1.3 billion in Q4 2015 and bottomed at $559.2 million in Q1 2011.
- Historically, Raw Materials has averaged $872.3 million across 5 years, with a median of $866.4 million in 2011.
- The sharpest annual moves came in 2011 and 2014: Raw Materials soared 96.23% in 2011, then dropped 13.38% in 2014.
- Over 5 years, Raw Materials stood at $697.6 million in 2011, then increased by 18.48% to $826.5 million in 2012, then gained by 26.96% to $1.0 billion in 2013, then decreased by 13.38% to $909.0 million in 2014, then surged by 46.53% to $1.3 billion in 2015.
- According to Business Quant data, Raw Materials over the past three periods registered $1.3 billion, $909.0 million, and $944.9 million for Q4 2015, Q4 2014, and Q2 2014 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 207.09 Bn | 193.10 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.68 Bn | 176.50 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 131.39 Bn | 123.54 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.79 Bn | 73.79 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.15 Bn | 55.97 Bn | 1.37 Bn |
| 6 | Moderna | 53.35 Bn | 48.21 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.40 Bn | 30.10 Bn | 992.69 Mn |
| 8 | Biogen | 31.66 Bn | 30.38 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.14 Bn | 29.14 Bn | 1.16 Mn |
| 10 | Insmed | 27.69 Bn | 26.53 Bn | 358.27 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2015 | 1.33 Bn |
| Dec 31, 2014 | 909.00 Mn |
| Jun 30, 2014 | 944.89 Mn |
| Dec 31, 2013 | 1.05 Bn |
| Dec 31, 2012 | 826.55 Mn |
| Dec 31, 2011 | 697.62 Mn |
| Sep 30, 2011 | 866.41 Mn |
| Jun 30, 2011 | 665.25 Mn |
| Mar 31, 2011 | 559.16 Mn |
| Dec 31, 2010 | 408.02 Mn |
| Sep 30, 2010 | 441.53 Mn |
| Dec 31, 2009 | 333.58 Mn |